These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38903942)

  • 21. Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.
    Belshe RB; Newman FK; Anderson EL; Wright PF; Karron RA; Tollefson S; Henderson FW; Meissner HC; Madhi S; Roberton D; Marshall H; Loh R; Sly P; Murphy B; Tatem JM; Randolph V; Hackell J; Gruber W; Tsai TF
    J Infect Dis; 2004 Dec; 190(12):2096-103. PubMed ID: 15551207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
    Rossey I; Saelens X
    Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
    [No Abstract]   [Full Text] [Related]  

  • 25. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
    Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
    Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease.
    Nambulli S; Escriou N; Rennick LJ; Demers MJ; Tilston-Lunel NL; McElroy AK; Barbeau DJ; Crossland NA; Hoehl RM; Schrauf S; White AG; Borish HJ; Tomko JA; Frye LJ; Scanga CA; Flynn JL; Martin A; Gerke C; Hartman AL; Duprex WP
    J Virol; 2024 May; 98(5):e0176223. PubMed ID: 38563762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New respiratory virus (chicken pox, influenza and respiratory syncytial virus) vaccines: efficacy, necessity and policy for the tropical world at present.
    Wiwanitkit V
    Hum Vaccin; 2009 Sep; 5(9):621-2. PubMed ID: 19363304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.
    Ascough S; Paterson S; Chiu C
    Front Immunol; 2018; 9():323. PubMed ID: 29552008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease.
    Lee YN; Hwang HS; Kim MC; Lee YT; Lee JS; Moore ML; Kang SM
    Antiviral Res; 2015 Mar; 115():1-8. PubMed ID: 25513755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stable Attenuation of Human Respiratory Syncytial Virus for Live Vaccines by Deletion and Insertion of Amino Acids in the Hinge Region between the mRNA Capping and Methyltransferase Domains of the Large Polymerase Protein.
    Xue M; Wang R; Harder O; Chen P; Lu M; Cai H; Li A; Liang X; Jennings R; La Perle K; Niewiesk S; Peeples ME; Li J
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Learning from the past: development of safe and effective COVID-19 vaccines.
    Su S; Du L; Jiang S
    Nat Rev Microbiol; 2021 Mar; 19(3):211-219. PubMed ID: 33067570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Viruslike particle vaccine induces protection against respiratory syncytial virus infection in mice.
    Quan FS; Kim Y; Lee S; Yi H; Kang SM; Bozja J; Moore ML; Compans RW
    J Infect Dis; 2011 Oct; 204(7):987-95. PubMed ID: 21881112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivalent vaccines effectively protect mice against influenza A and respiratory syncytial viruses.
    Raman SNT; Zetner A; Hashem AM; Patel D; Wu J; Gravel C; Gao J; Zhang W; Pfeifle A; Tamming L; Parikh K; Cao J; Tam R; Safronetz D; Chen W; Johnston MJW; Wang L; Sauve S; Rosu-Myles M; Domselaar GV; Li X
    Emerg Microbes Infect; 2023 Dec; 12(1):2192821. PubMed ID: 36927227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins.
    Tripp RA; Stambas J
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.
    Chan Y; Ng SW; Singh SK; Gulati M; Gupta G; Chaudhary SK; Hing GB; Collet T; MacLoughlin R; Löbenberg R; Oliver BG; Chellappan DK; Dua K
    Life Sci; 2021 Sep; 280():119744. PubMed ID: 34174324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines.
    Simoes EA; Tan DH; Ohlsson A; Sales V; Wang EE
    Vaccine; 2001 Dec; 20(5-6):954-60. PubMed ID: 11738763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
    Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.